News

Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume

Customer Cash Receipts (A$'000) Customer Cash Receipts (A$'000)MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”,…

1 year ago

Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023

CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has completed the submission…

1 year ago

Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform

The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new cannabis care platform will offer…

1 year ago

Jushi Holdings Inc. to Report Second Quarter 2023 Financial Results on August 11, 2023

BOCA RATON, Fla., July 28, 2023 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),…

1 year ago

Press release: Online availability of Sanofi’s half-year financial report for 2023

Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces that its half-year financial report…

1 year ago

Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

1 year ago

Biogen to Acquire Reata Pharmaceuticals

SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia  Proposed acquisition represents meaningful step forward…

1 year ago

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics…

1 year ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         

OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading…

1 year ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA…

1 year ago